Icotinib for Completed Resected IB NSCLC With EGFR Mutation

Inclusion Criteria: * Written informed consent provided. * Males or females, Aged 18-75 years. * Able to comply with the required protocol and follow-up procedures, and able to receive oral medications. * Had completely resected pathological confirmed stage IIA-IIIA NSCLC. * EGFR activating mutation in exon 19 or 21. * Patient who can start the investigational therapy within 3-6 weeks after the complete resection. * ECOG performance status of 0-1. * Had a life expectancy of 12 weeks or more. * Adequate hematological function, adequate liver function and renal function. * Female patients, except those who are postmenopausal or surgically sterilized, must have a negative pre-study serum or urine pregnancy test. Exclusion Criteria: * Had had previous chemotherapy, radiotherapy, or agents directed at the HER axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab). * Inability to comply with protocol or study procedures. * Had a history another malignancy in the last 5 years with the exception of cured basal cell carcinoma of the skin, cured in situ carcinoma of the uterine cervix and cured epithelial carcinoma of the bladder. * Any evidence confirmed tumor recurrence before investigational therapy. * Known severe hypersensitivity to icotinib or any of the excipients of this product. * Evidence of clinically active interstitial lung disease. * Eye inflammation not fully controlled or conditions predisposing the subject to this. * Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease). * Known human immunodeficiency virus (HIV) infection. * Pregnancy or breast-feeding women. * Ingredients mixed with small cell lung cancer patients. * History of neurologic or psychiatric disorders.